Catalyst
Slingshot members are tracking this event:
Sarepta (SRPT) Doses First Patient in Phase 1 4045-101 Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SRPT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 01, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
First Patient, Dosing Of First Patient, Phase 1 Trial, 4045-101, Dose-titration, Open-label Extension Study, Srp-4045, Advanced Stage Duchenne Muscular Dystrophy
